Editas Medicine GAAP EPS of -$0.63 misses by $0.25, revenue of $3.58M beats by $1.78M
Source: SeekingAlpha
2025-08-12 16:46:57 ET
More on Editas Medicine
- Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible
- Gene editors steady despite latest leadership shake-up at FDA
- RFK Jr. looks to fast track rare disease drug approvals (updated)
- Seeking Alpha’s Quant Rating on Editas Medicine
- Historical earnings data for Editas Medicine
Read the full article on Seeking Alpha
For further details see:
Editas Medicine GAAP EPS of -$0.63 misses by $0.25, revenue of $3.58M beats by $1.78M
Editas Medicine Inc.
NASDAQ: EDIT
EDIT Trading
-2.57% G/L:
$2.465 Last:
588,093 Volume:
$2.60 Open:
EDIT Latest News
March 09, 2026 07:00:00 am
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
EDIT Stock Data
$174,737,401
95,568,668
0.4%
71
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
